Cancer Target Collaboration Agreement Signed Between MedImmune and Georgetown University

28-Sep-2005

MedImmune, Inc. announced that it has entered into a licensing and collaboration agreement with Georgetown University for the development of monoclonal antibodies (MAbs) targeting anaplastic lymphoma kinase (ALK), a member of the insulin receptor family of tyrosine kinases. ALK is believed to play an important role in the growth of solid tumors including those associated with prostate, colon and lung cancers.

Under the terms of the agreement, MedImmune will receive exclusive worldwide rights to develop oncology therapies using MAbs targeting ALK. MedImmune will be responsible for the clinical development and commercialization of any resulting products. Georgetown University will receive an upfront payment as well as potential development milestone payments and royalties on future marketed products. The organizations will also participate in an ongoing research collaboration as part of the agreement.

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous